Products & Programs PharmacyCommercialMarch 1, 2023

Clinical Criteria updates for specialty pharmacy are available

Effective for dates of service on and after May 1, 2023, the following Clinical Criteria were developed and might result in services that were previously covered but may now be found to be not medically necessary.

CC-0003

Immunoglobulins

CC-0062

Tumor necrosis factor antagonists

CC-0100

Istodax (romidepsin)

CC-0168

Tecartus (brexucabtagene autoleucel)

CC-0205

Fyarro (siroliumus albumin bound)

Access the Clinical Criteria document information.

Anthem Blue Cross and Blue Shield (Anthem)’s prior authorization clinical review of non-oncology specialty pharmacy drugs will be managed by Anthem’s medical specialty drug review team. Drugs used for the treatment of oncology will be managed by Carelon Medical Benefits Management, Inc.,* a separate company.

* Carelon Medical Benefits Management, Inc. is an independent company providing some utilization review services on behalf of the health plan.

GABCBS-CM-015977-22

PUBLICATIONS: March 2023 Anthem Provider News - Georgia